Total Payments
$613,474
2024 Payments
$59,591
Companies
21
Transactions
321
Payment Breakdown by Category
Consulting$426,122 (69.5%)
Other$102,299 (16.7%)
Travel$64,351 (10.5%)
Research$16,428 (2.7%)
Food & Beverage$4,243 (0.7%)
Education$31.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $426,122 | 130 | 69.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $102,299 | 40 | 16.7% |
| Travel and Lodging | $64,351 | 65 | 10.5% |
| Unspecified | $16,428 | 11 | 2.7% |
| Food and Beverage | $4,243 | 74 | 0.7% |
| Education | $31.50 | 1 | 0.0% |
Payments by Type
General
$597,046
310 transactions
Research
$16,428
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $179,295 | 128 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $164,411 | 80 | $0 (2024) |
| SANOFI US SERVICES INC. | $52,575 | 13 | $0 (2023) |
| AstraZeneca UK Limited | $48,167 | 24 | $0 (2024) |
| Chiesi USA, Inc. | $45,899 | 12 | $0 (2022) |
| Boehringer Ingelheim International GmbH | $17,988 | 7 | $0 (2021) |
| AstraZeneca AB | $17,776 | 9 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $17,612 | 11 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,926 | 3 | $0 (2022) |
| GENZYME CORPORATION | $14,180 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,591 | 29 | GlaxoSmithKline, LLC. ($17,966) |
| 2023 | $34,654 | 21 | GlaxoSmithKline, LLC. ($14,000) |
| 2022 | $67,597 | 25 | Chiesi USA, Inc. ($17,920) |
| 2021 | $76,595 | 33 | GlaxoSmithKline, LLC. ($30,639) |
| 2020 | $87,294 | 50 | GlaxoSmithKline, LLC. ($38,703) |
| 2019 | $145,203 | 61 | AstraZeneca Pharmaceuticals LP ($80,621) |
| 2018 | $87,381 | 57 | GlaxoSmithKline, LLC. ($21,883) |
| 2017 | $55,160 | 45 | GlaxoSmithKline, LLC. ($18,858) |
All Payment Transactions
321 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $671.25 | General |
| 12/12/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,509.00 | General |
| 11/13/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $2,100.00 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $6,981.00 | General |
| 09/15/2024 | GENZYME CORPORATION | — | — | In-kind items and services | $250.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | ||||||
| 09/14/2024 | GENZYME CORPORATION | — | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | ||||||
| 09/09/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 09/07/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,815.00 | General |
| 09/07/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $45.45 | General |
| 08/28/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,837.50 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/28/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,837.50 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/28/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | Cash or cash equivalent | $1,575.00 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,282.25 | General |
| 08/06/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,148.00 | General |
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,074.00 | General |
| 07/16/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,074.00 | General |
| 05/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $35.31 | General |
| 05/18/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| 05/18/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $43.84 | General |
| 05/10/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| 05/08/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $90.92 | General |
| 04/10/2024 | Aero US Inc | AEROGEN SOLO NEBULIZER SYSTEM (Device), AEROGEN USB CONTROLLER SYSTEM, AEROGEN SOLO NEBULIZER SYSTEM | Consulting Fee | Cash or cash equivalent | $2,706.19 | General |
| Category: RESPIRATORY | ||||||
| 04/10/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $990.00 | General |
| 03/22/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 03/19/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,148.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $7,350 | 4 |
| NONE | CHIESI USA, INC. | $6,972 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | GENZYME CORPORATION | $1,250 | 3 |
About Dr. Bartolome Celli, MD
Dr. Bartolome Celli, MD is a Pulmonary Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1699762773.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bartolome Celli, MD has received a total of $613,474 in payments from pharmaceutical and medical device companies, with $59,591 received in 2024. These payments were reported across 321 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($426,122).
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Boston, MA
- Active Since 10/04/2005
- Last Updated 08/06/2012
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1699762773
Products in Payments
- FASENRA (Drug) $104,846
- TRELEGY ELLIPTA (Drug) $58,656
- DUPIXENT (Biological) $46,911
- NO PRODUCT DISCUSSED (Drug) $32,213
- STIOLTO RESPIMAT (Drug) $32,073
- BREZTRI (Drug) $24,055
- BREZTRI AEROSPHERE (Drug) $19,222
- SPIRIVA (Drug) $3,438
- QVA149A (Drug) $3,373
- Pulmonx Endobronchial Valve EBV (Device) $3,325
- STIOLTO (Drug) $2,760
- AEROGEN SOLO NEBULIZER SYSTEM (Device) $2,706
- ANORO (Drug) $1,605
- NUCALA (Biological) $975.00
- CHARTIS CATHETER (Device) $600.00
- BEVESPI AEROSPHERE (Drug) $31.50
- Arikayce (Drug) $29.00
- XOLAIR (Biological) $20.69
- ANORO ELLIPTA (Drug) $14.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Boston
Adnan Majid, Md, MD
Pulmonary Disease — Payments: $424,602
Pulmonary Disease $424,602
Avrum Spira, M.d, M.D
Pulmonary Disease — Payments: $157,114
Pulmonary Disease $157,114
Dr. Tufik Assad, M.d, M.D
Pulmonary Disease — Payments: $151,341
Pulmonary Disease $151,341
Dr. Benjamin Medoff, Md, MD
Pulmonary Disease — Payments: $136,103
Pulmonary Disease $136,103
Kelsey Sack, Md/Phd, MD/PHD
Pulmonary Disease — Payments: $82,500
Pulmonary Disease $82,500
Jason Beattie, Md, MD
Pulmonary Disease — Payments: $62,211
Pulmonary Disease $62,211